Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Location contact
Barry Borlaug, MD
CONTACT
Barry Borlaug, MD
PRINCIPAL_INVESTIGATOR
Circulatory Failure Research Team
CONTACT
NCT Number: NCT05935605
The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Barry Borlaug, MD
CONTACT
Barry Borlaug, MD
PRINCIPAL_INVESTIGATOR
Circulatory Failure Research Team
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
Peak exercise cardiac output (L/min) will be measured using the direct Fick technique during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
Peak exercise VO2 (ml/kg/min) will be measured using expired gas analysis collected during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
TAPSE is measured as the displacement (in mm) of the lateral tricuspid annulus toward the apex during systole measured using transthoracic echocardiography during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
TAPSE/PASP ratio (mm/mmHg) will be measured using transthoracic echocardiography during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
Extravascular Lung Fluid Content (B-line score) will be measured using lung ultrasound during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
Peripheral venous pressure will be measured through a standard upper extremity peripheral IV line. Peripheral venous pressure (PVP) is reported in millimeters of mercury (mmHg)
Time frame: Baseline
Right Atrial (RA) pressure will be measured during the invasive hemodynamic assessment by right heart catheterization.
Time frame: Baseline
The same pressures that are measured in the supine position will be measured in the upright position in a subset of patients. These measures will be obtained at rest and during exercise (for those receiving this).
Contact information is provided by the study sponsor or research team.
Barry Borlaug, MD
CONTACT
Circulatory Failure Research Team
CONTACT
Mayo Clinic
Other
Comparison of Noninvasively-Obtained Echocardiographic Doppler Parameters With Simultaneously-Measured Invasive Hemodynamics in Patients Referred for Right Heart Catheterization
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07561034
Cardiovascular Diseases, Hypertension
Rochester, New York, United States
View Trial DetailsNCT06336798
Cardiovascular Diseases, Hypertension
Atlanta, Georgia, United States
View Trial DetailsNCT01730092
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT07214376
Cardiovascular Diseases, Heart Diseases
Houma, Louisiana, United States
View Trial Details